Hong Seng's unit signs collaborative agreement with Mediven

Hong Seng executive director and HS Bio director Christopher Chan

KUALA LUMPUR: Hong Seng Consolidated Bhd’s healthcare arm HS Bio Sdn Bhd has signed a collaboration agreement with Mediven Innovation Ventures Sdn Bhd to expand their respective coverage in the healthcare sector.

Mediven is a group of companies involved in the healthcare sector and has approvals, licences accreditations

Moving forward, HS Bio and Mediven will jointly explore opportunities and markets for their respective products and may jointly pursue tenders and bids for projects by providing a more comprehensive range of solutions.

“The collaboration with Mediven represents a new opportunity for HS Bio to expand into yet another important component in healthcare which is the manufacturing of medical devices.

“We find that Mediven’s proven quality in internationally-recognised assessments, as well as its success in executing projects and exporting their products, will certainly lend us a great hand in bidding for new projects and gaining exposure in overseas markets,” Hong Seng executive director and HS Bio director Christopher Chan said in a statement.

Meanwhile, Mediven operations director Dr Lim Li Sze said: “Mediven is pleased to be a part of this new partnership which will further expand its reach and range of offerings in the healthcare sector.”

“We believe that by combining our strengths as a leading molecular diagnostics provider in Malaysia with HS Bio’s wide-reaching healthcare supply chain solutions, both parties will be able to make a significant impact in improving health and preventing infectious diseases.

“This is aligned with Mediven’s vision to deliver quality medical diagnostics faster and better, locally and globally,” Lim said.